[Hemosorption in the prevention of severe forms of hemolytic disease of the newborn in rhesus sensitization].
A total of 164 hemoperfusions were administered to 60 pregnant patients with Rh sensitization and a history of perinatal death of the newborns from hemolytic disease. Hemoperfusion was found to decelerate the progress of hemolytic disease of the newborns promoting delivery of babies with more benign forms of the disease. The method efficacy was 76%. Dynamic follow-up of fetal functional status over the course of hemosorption treatment by examinations of biophysical profiles and ultrasonic dopplerometry has shown no negative effects of this treatment modality on fetal status.
Konopliannikov
A G
AG
Saĭkina
E A
EA
Goriushina
N B
NB
Panina
O B
OB
D000328:Adult; D004899:Erythroblastosis, Fetal / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D005069:Evaluation Studies as Topic; D005260:Female; D005333:Fetus / Q000503:physiopathology; D006464:Hemoperfusion; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D012203:Rh Isoimmunization / Q000150:complications / Q000503:physiopathology / Q000628:therapy*
Gemosorbtsiia v profilaktike tiazhelykh form gemoliticheskoĭ bolezni novorozhdennogo pri rezus-sensibilizatsii.